Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.74%||176.97||0.7%||$1352.49m|
|BMY||Bristol-Myers Squibb Co.||0.36%||76.23||1.0%||$1197.90m|
|MRK||Merck & Co., Inc.||1.26%||93.25||0.7%||$1136.00m|
|LLY||Eli Lilly & Co.||4.49%||299.11||1.1%||$892.99m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.65%||141.96||0.0%||$458.27m|
|HZNP||Horizon Therapeutics Plc||1.13%||90.35||5.4%||$200.40m|
|NVO||Novo Nordisk A/S||3.49%||107.68||0.1%||$190.60m|
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.